The new SPAC intends to search for companies in the biopharmaceutical sector, with a focus on disruptive technologies with the potential to transform healthcare and dramatically improve the lives of patients. Arbor Rapha Capital Bioholdings I is led by CEO and President Ivan Kaufman, CSO Kevin Slawin, CFO Paul Elenio, Secretary & VP William Connolly, and Treasurer John Natalone.
Total SPAC deal count for 2021 year-to-date is now 500. This offering is expected to close on Tuesday, November 2.
Cantor Fitzgerald & Co. (“Cantor”) is acting as sole book-running manager. Skadden, Arps, Slate, Meagher & Flom LLP is serving as Issuer’s Counsel with Ellenoff Grossman & Schole LLP serving as Underwriter’s Counsel. Marcum LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.